Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: A biomarker analysis of the inTandem3 clinical trial
Effekte von Sotagliflozin auf Marker des Volumenstatus und der Natriumhandhabung bei Patient:innen mit Typ-1-Diabetes: Biomarker-Analyse der inTandem3-Studie
Diabetes, Obesity and Metabolism · 2026-04 · 28 (4) · 3254-3263
DOI: 10.1111/dom.70520 ↗Auf einen Blick
In einer Post-hoc-Analyse der inTandem3-Studie veränderte Sotagliflozin mehrere Marker der Volumenhomöostase bei Typ-1-Diabetes. Renin und NT-proBNP blieben unverändert, während andere Biomarker anstiegen oder abnahmen.
Fragestellung
Welche Effekte hat Sotagliflozin zusätzlich zu Insulin auf Marker der Neurohormonaktivierung und Volumenhomöostase bei Typ-1-Diabetes?
Methode
Post-hoc-Analyse der randomisierten, doppelblinden, placebokontrollierten inTandem3-Studie; Sotagliflozin 400 mg/Tag versus Placebo zusätzlich zu Insulin; Biomarker zu Baseline und Woche 24.
Ergebnisse
362 Teilnehmende. Sotagliflozin erhöhte Copeptin um 33 %, FE Li um 14 % und FE Glucose um 60-fach (alle p < 0,01), veränderte Renin und NT-proBNP nicht (beide p ≥ 0,11) und senkte KIM-1 um 19 % (p = 0,03).
Schlussfolgerung der Autor:innen
Bei Typ-1-Diabetes erhöhte Sotagliflozin Copeptin, FE Li und FE Glucose ohne Veränderung von Renin und reduzierte Marker der Nierenschädigung; zudem stiegen Hämoglobin und Hämatokrit.
Kernaussagen
- Copeptin, FE Li und FE Glucose nahmen unter Sotagliflozin zu
- Renin und NT-proBNP blieben im Vergleich zu Placebo unverändert
- KIM-1 sank; Hämoglobin und Hämatokrit stiegen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 27.01.2026. Verfasst von Massimo Nardone und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Glycosides, Sodium, Hypoglycemic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Lexicon Pharmaceuticals, Inc.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Sotagliflozin, an inhibitor of sodium‐glucose co‐transporter (SGLT)‐1 and 2, reduces albuminuria, slows GFR decline, and may have diuretic and osmoregulatory effects. The effect of sotagliflozin added to insulin was assessed on markers of neurohormone activation and volume homeostasis in patients with type 1 diabetes (T1D). Materials and Methods This is a post‐hoc analysis of the randomised, double‐blinded, placebo‐controlled inTandem3 trial, which assessed efficacy of sotagliflozin 400 mg/d versus placebo as an adjunct to insulin. The present biomarker analysis included 362 participants (26%) who had biological samples collected at baseline and week 24. Plasma renin, copeptin, serum N‐terminal pro b‐type natriuretic peptide (NT‐proBNP), and markers of tubular injury, inflammation, haematopoiesis, and iron homeostasis were measured at baseline and following week 24 treatment; fractional excretion of lithium (FE Li ) and glucose (FE Glucose ) were calculated.
Results
Participants were 46 years of age (60% female) with a mean eGFR and median UACR of 88.4 mL/min/1.73 m 2 and 7.5 mg/g, respectively. Sotagliflozin increased copeptin, FE Li , and FE Glucose by 33%, 14%, and 60‐fold, respectively (all p < 0.01), but did not change renin or NT‐proBNP (both p ≥ 0.11) compared to placebo. Further, urinary kidney injury molecule‐1 decreased by 19% ( p = 0.03). Haemoglobin and haematocrit increased (both p < 0.01), without altering inflammatory, erythropoietic, or iron biomarkers (all p ≥ 0.11).
Conclusions
In this T1D population, sotagliflozin increased copeptin levels, FE Li , and FE Glucose without altering renin, reflecting adaptive mechanisms that preserve sodium and fluid balance and protect against volume depletion. Sotagliflozin also decreased markers of kidney injury and increased haematocrit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
- Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
- Lexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA.
- Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.
ORCID-Profile: Hiddo J L Heerspink, David Z I Cherney, Marcel H A Muskiet
Förderung
- Lexicon Pharmaceuticals, Inc
Zitieren
APA
Nardone, M., Moedt, E., Heerspink, H. J. L., Davies, M. J., Girard, M., Cherney, D. Z. I., & Muskiet, M. H. A. (2026). Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: A biomarker analysis of the inTandem3 clinical trial. Diabetes, Obesity and Metabolism, 28(4), 3254-3263. https://doi.org/10.1111/dom.70520
Vancouver
Nardone M, Moedt E, Heerspink HJL, Davies MJ, Girard M, Cherney DZI, et al. Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: A biomarker analysis of the inTandem3 clinical trial. Diabetes, Obesity and Metabolism. 2026;28(4):3254-3263. doi:10.1111/dom.70520
BibTeX
@article{Nardone2026,
author = {Nardone, Massimo and Moedt, Erik and Heerspink, Hiddo J L and Davies, Michael J and Girard, Manon and Cherney, David Z I and Muskiet, Marcel H A},
title = {Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: A biomarker analysis of the inTandem3 clinical trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {4},
pages = {3254--3263},
doi = {10.1111/dom.70520}
}
EUVIMED